Chang Jiang Shang Bao·2025-12-19 00:18Core Viewpoint - The company, Baiyunshan, is actively expanding its presence in the East China market through strategic acquisitions, including the purchase of Zhejiang Pharmaceutical Industry Co., Ltd. for 501 million yuan, aimed at optimizing its industrial layout in the region [1][2]. Group 1: Acquisition Details - Baiyunshan's subsidiary, Guangzhou Pharmaceutical, will acquire 100% of Zhejiang Pharmaceutical, which has a strong distribution network across Zhejiang province and holds licenses for key pharmaceutical products [2][3]. - The acquisition is part of a broader strategy to enhance Baiyunshan's market influence in East China, where it has experienced a decline in revenue [1][4]. Group 2: Financial Performance - In the first three quarters of 2025, Baiyunshan reported a net profit attributable to shareholders of 3.31 billion yuan, marking a year-on-year increase of 4.78%, reversing a previous decline [7]. - The company's revenue from the East China market was 3.449 billion yuan in the first half of 2025, a decrease from 3.601 billion yuan in the same period the previous year [4]. Group 3: Strategic Partnerships - Baiyunshan has also invested in Nanjing Pharmaceutical, acquiring an 11.04% stake for approximately 749 million yuan, which positions it as the second-largest shareholder and facilitates collaboration in the pharmaceutical distribution sector [3][4]. - The partnership with Nanjing Pharmaceutical is expected to enhance Baiyunshan's market penetration in Jiangsu, Anhui, Hubei, and Fujian provinces [3]. Group 4: Market Position and Brand Value - Baiyunshan operates across four main sectors: traditional Chinese medicine, health products, commercial operations, and medical services, with a strong portfolio of over 2,000 product specifications [5][6]. - The company ranks first in brand value within the pharmaceutical and health sector in China, with several of its brands recognized among the top in the industry [5].